We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Man Study With SLV341

This study has been terminated.
(The study was terminated on June 25th, 2009 due to strategic decision)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00887445
First Posted: April 24, 2009
Last Update Posted: April 28, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Quintiles, Inc.
Information provided by:
Solvay Pharmaceuticals
  Purpose
First in man study with single and multiple rising doses with SLV341

Condition Intervention Phase
Diabetes Drug: SLV341 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination. [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters: Plasma: Cmax, tmax, AUC, t½, λz, CL/F, and Vz/F. Urine: Aeurine, fe, and CLR [ Time Frame: 1 - 28 days ]
  • Pharmacodynamic parameters: biochemistry and 24 h Holter monitoring. [ Time Frame: 28 days ]
  • Interaction with Midazolam [ Time Frame: 24 hours ]

Enrollment: 87
Study Start Date: July 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: SLV341
5 - 1000mg once daily
Placebo Comparator: B Drug: placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria
Inclusion Criteria healthy Exclusion Criteria not healthy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00887445


Locations
United Kingdom
S341.1.001 Site #
London, United Kingdom
Sponsors and Collaborators
Solvay Pharmaceuticals
Quintiles, Inc.
Investigators
Study Director: Ingrid Meuwsen Solvay Pharmaceuticals
  More Information

ClinicalTrials.gov Identifier: NCT00887445     History of Changes
Other Study ID Numbers: S341.1.001
2007-007196-17
00887445
First Submitted: January 30, 2009
First Posted: April 24, 2009
Last Update Posted: April 28, 2010
Last Verified: April 2010

Keywords provided by Solvay Pharmaceuticals:
First in Man
SLV341
diabetes